Literature DB >> 16685140

Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy.

Mustafa Cirit1, Omer Toprak, Murat Yesil, Serdar Bayata, Nursen Postaci, Lara Pupim, Ertap Esi.   

Abstract

BACKGROUND/AIMS: The aim of the present study was to assess the influence of chronic angiotensin-converting enzyme (ACE) inhibitor administration on the development of contrast-induced nephropathy (CIN) in patients undergoing coronary angiography.
METHODS: A total of 230 patients with renal insufficiency and age > or =65 years were divided into two groups according to prior use of ACE inhibitors (ACE inhibitor group, n = 109; control group, n = 121). CIN was defined as an increase of > or =25% in creatinine over the baseline value within 48 h of angiography.
RESULTS: CIN occurred in 17 patients (15.6%) in the ACE inhibitor group and 7 patients (5.8%) in the control group (p = 0.015). Serum creatinine level increased from 1.34 +/- 0.20 to 1.53 +/- 0.27 mg/dl in the ACE inhibitor group and from 1.33 +/- 0.18 to 1.45 +/- 0.19 mg/dl in the control group (p < 0.001). Chronic ACE inhibitor administration was a risk indicator of CIN [odds ratio 3.37; 95% confidence interval 1.14-9.94; p = 0.028]. Multi-vessel coronary involvement (p = 0.001), hypoalbuminemia (p = 0.005), diabetes mellitus (p = 0.006), GFR < or =40 ml/min (p = 0.010), and congestive heart failure (p = 0.024) were other risk indicators of CIN.
CONCLUSION: Chronic ACE inhibitor administration is a risk for developing CIN in elderly patients with renal insufficiency. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16685140     DOI: 10.1159/000093255

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  23 in total

1.  Renin-Angiotensin System Blockade after Acute Kidney Injury (AKI) and Risk of Recurrent AKI.

Authors:  Chi-Yuan Hsu; Kathleen D Liu; Jingrong Yang; David V Glidden; Thida C Tan; Leonid Pravoverov; Sijie Zheng; Alan S Go
Journal:  Clin J Am Soc Nephrol       Date:  2019-12-16       Impact factor: 8.237

Review 2.  Prevention and Management of AKI in ACS Patients Undergoing Invasive Treatments.

Authors:  Ravi A Thakker; Aiham Albaeni; Haider Alwash; Syed Gilani
Journal:  Curr Cardiol Rep       Date:  2022-08-04       Impact factor: 3.955

3.  Stopping versus continuing renin-angiotensin-system inhibitors after acute kidney injury and adverse clinical outcomes: an observational study from routine care data.

Authors:  Roemer J Janse; Edouard L Fu; Catherine M Clase; Laurie Tomlinson; Bengt Lindholm; Merel van Diepen; Friedo W Dekker; Juan-Jesus Carrero
Journal:  Clin Kidney J       Date:  2022-01-12

Review 4.  [Iodinated contrast agent-induced nephropathy].

Authors:  C Erley
Journal:  Radiologe       Date:  2007-09       Impact factor: 0.635

Review 5.  Inhibition of the renin-angiotensin system and chronic kidney disease.

Authors:  Kostas C Siamopoulos; Rigas G Kalaitzidis
Journal:  Int Urol Nephrol       Date:  2008-08-14       Impact factor: 2.370

6.  The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy.

Authors:  Jordan L Rosenstock; Robert Bruno; Jin K Kim; Lev Lubarsky; Robert Schaller; Georgia Panagopoulos; Maria V DeVita; Michael F Michelis
Journal:  Int Urol Nephrol       Date:  2008-04-26       Impact factor: 2.370

7.  Preventing Contrast-induced Renal Failure: A Guide.

Authors:  Michela Faggioni; Roxana Mehran
Journal:  Interv Cardiol       Date:  2016-10

Review 8.  Contrast-induced nephropathy--a review of current literature and guidelines.

Authors:  Artur Maliborski; Paweł Zukowski; Grzegorz Nowicki; Romana Bogusławska
Journal:  Med Sci Monit       Date:  2011-09

9.  Contrast-induced nephropathy in interventional cardiology.

Authors:  Doron Sudarsky; Eugenia Nikolsky
Journal:  Int J Nephrol Renovasc Dis       Date:  2011-07-12

Review 10.  Angiotensin-Converting Enzyme Inhibitors and Contrast-Associated Acute Kidney Injury After Coronary Angiography and Intervention.

Authors:  Melissa Wasilewski; Sumon Roy; Nilang G Patel; Ion S Jovin
Journal:  Am J Cardiovasc Drugs       Date:  2020-12-28       Impact factor: 3.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.